Global pharma major Lupin has launched Rivaroxaban for Oral Suspension, 1 mg/mL in the United States.

The product is a bioequivalent to Xarelto for Oral Suspension, 1 mg/mL, of Janssen Pharmaceuticals. It is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least five days of initial parenteral anticoagulant treatment.

It is also indicated for treatment of thromboprophylaxis in pediatric patients two years and older with congenital heart disease after the Fontan procedure.

Rivaroxaban for Oral Suspension had estimated annual sales of USD 11 million in the US.

Headquartered in Mumbai, India, Lupin has a presence in over 100 markets. Its portfolio spans branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has 15 state-of-the-art manufacturing facilities and seven research centres worldwide and holds a strong position in key therapeutic areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.